(19)
(11) EP 2 155 671 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.02.2018 Bulletin 2018/08

(45) Mention of the grant of the patent:
20.12.2017 Bulletin 2017/51

(21) Application number: 08760496.3

(22) Date of filing: 04.06.2008
(51) International Patent Classification (IPC): 
C07D 207/12(2006.01)
A61P 25/00(2006.01)
 A61K 31/40(2006.01)
(86) International application number:
PCT/EP2008/056915
(87) International publication number:
WO 2008/148801 (11.12.2008 Gazette 2008/50)

(54)

DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION

DISUBSTITUIERTE PHENYLPYRROLIDINE ALS MODULATOREN DER KORTIKALEN KATECHOLAMINERGEN NEUROTRANSMISSION

PHÉNYLPYRROLIDINES DISUBSTITUÉES EN TANT QUE MODULATEURS DE LA NEUROTRANSMISSION CATÉCHOLAMINERGIQUE CORTICALE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 05.06.2007 SE 0701387
05.06.2007 US 941994 P

(43) Date of publication of application:
24.02.2010 Bulletin 2010/08

(73) Proprietor: Integrative Research Laboratories Sweden AB
413 46 Göteborg (SE)

(72) Inventors:
  • SONESSON, Clas
    S-413 46 Göteborg (SE)
  • SWANSON, Lars
    S-413 46 Göteborg (SE)
  • PETTERSSON, Fredrik
    S-413 46 Göteborg (SE)
  • WATERS, Nicholas
    S-413 46 Göteborg (SE)
  • WATERS, Susanna
    S-413 46 Göteborg (SE)

(74) Representative: Valea AB 
Anna Lindhs Plats 4
211 19 Malmö
211 19 Malmö (SE)


(56) References cited: : 
WO-A-92/18475
US-A- 3 118 907
 WO-A-2005/121092
   
  • WILLIAM A. GOULD ET AL.: "Pyrrolidines. IX. 3-Aryl-3-pyrrolidinols" JOURNAL OF MEDICINAL CHEMISTRY., vol. 7, no. 1, 1964, pages 60-67, XP002505965 USAMERICAN CHEMICAL SOCIETY. WASHINGTON. cited in the application
  • SONESSON C ET AL: "SUBSTITUTED (S)-PHENYLPIPERIDINES AND RIGID CONGENERS AS PREFERENTIAL DOPAMINE AUTORECEPTOR ANTAGONISTS: SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS" JOURNAL OF MEDICINAL CHEMISTRY, US AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 37, no. 17, 1 January 1994 (1994-01-01), pages 2735-2753, XP000925302 ISSN: 0022-2623 cited in the application
  • SONESSON C ET AL: "Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 7, no. 3, 4 February 1997 (1997-02-04), pages 241-246, XP004136001 ISSN: 0960-894X cited in the application
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).